|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Competition between fusion-evaporation and multifragmentation in central collisions in ^(58)Ni+^(48)Ca at 25A MeV显示文摘The experimental data concerning the58Ni+48Ca reaction at Elab(Ni)=25A MeV,collected by using the CHIMERA 4π device,have been analyzed in order to investigate the competition among different reaction mechanisms for central collisions in the Fermi energy domain.As a main criterion for centrality selection we have chosen the flow angle(flow) method,making an event-by-event analysis that considers the shape of events,as it is determined by the eigenvectors of the experimental kinetic-energy tensor.For the selected central events(flow >60°) some global variables,good to characterize the pattern of central collisions have been constructed.The main features of the reaction products were explored by using different constraints on some of the relevant observables,like mass and velocity distributions and their correlations.Much emphasis was devoted,for central collisions,to the competition between fusion-evaporation processes with subsequent identification of a heavy residue and a possible multifragmentation mechanism of a well defined(if any) transient nuclear system.Dynamical evolution of the system and pre-equilibrium emission were taken into account by simulating the reactions in the framework of transport theories.Different approaches have been envisaged(dynamical stochastic BNV calculations + sequential SIMON code,QMD,CoMD,etc.).Preliminary comparison of the experimental data with BNV calculations shows reasonable agreement with the assumption of sequential multifragmentation emission in the mass region of IMFs close to the heavy residues.Possible deviations from sequential processes were found for those IMFs in the region of masses intermediate between the mass of heavy residues and the mass of light IMFs.Further simulations are in progress.The experimental analysis will be enriched also by information obtained inspecting the IMF-IMF correlation function,in order to elucidated the nature of space-time decay property of the emitting source associated with events having the largest IMF multiplicity. | FRANCALANZA L ABBONDANNO U AMORINI F BARLINI S BINI M BOUGAULT R BRUNO M CARDELLA G CASINI G AGOSTINO M D' De FILIPPO V De SANCTIS J GERACI E GIUSSANI A GRAMEGNA F GUIOT B KRAVCHUK V La GUIDARA E LANZALONE G Le NEINDRE N MAIOLINO C MARINI P MORELLI L OLMI A PAGANO A PAPA M PIANTELLI S PIRRONE S POLITI G POGGI G PORTO F RUSSOTTO P RIZZO F VANNINI G VANNUCCI L | 2013 | Nuclear Science and Techniques2013，24，5： | 2 |
| 2 | Human bone marrow derived Mesenchymal stem cells in the treatlnent of gliomas 显示文摘 | Nakamizo A Marini F Amano T | 2005 | CancerRes2005，65，8： | 1 |
| 3 | The Participation of mesenchymal stem cells in tumor stroma formation and their application as tar geted-gene delivery vehicles显示文摘 | Hall B Andreeff M Marini F | 2007 | Handb Exp Pharmacol2007，，180： | 1 |
| 4 | Bone marrow-derlved mensenchymal stem as vehicles for interferon-beta delivery into tumors 显示文摘 | STUDENY M MARINI F CHAMPLIN C | 2002 | Cancer Res2002，62，： | 1 |
| 5 | Determination of ambroxol in bionlogical Material by gas chromatography with electron-capture Detection显示文摘 | Colombl L Marcucci F Marini MG | 1990 | Chromatogr1990，530，1： | 1 |
| 6 | Pemetrexed as first-linetherapy for non-squamous non-small cell lung cancer显示文摘 | Ricciardi S Tomao S de Marinis F | 2009 | TherClin Risk Manag2009，5，： | 1 |
| 7 | Sympathetic skin response and cardiovascular autonomic function tests in Par- kinson's disease and multiple system atrophy with autonomic failure 显示文摘 | DE MARINIS M STOCCHI F GREGORI B | 2000 | Mov Disord2000，15，6： | 1 |
| 8 | Stroke in young adults in the community-based L'Aquila registry:inci-dence and prognosis显示文摘 | Marini C Totaro R De Santis F | 2001 | Stroke2001，32，1： | 1 |
| 9 | Stroke in young adults in the community-based L'Aquila registry:incidence and prognosis显示文摘 | Marini C Totaro R De Stantis F | 2001 | Stroke2001，32，1： | 1 |
| 10 | Phase Ⅲ randomized trial comparing three platinum - based doublets in advanced non - small cell lung cancer 显示文摘 | Scagliotti GV De Marinis F Rinaldi M | 2002 | J Clin Oncol2002，20，： | 1 |
| 11 | Contribution of atrial fibrillation to incidence and outcome of ischemic stroke : results from a population-based study 显示文摘 | Marini C De Santis F Sacco S | 2005 | Stroke2005，36，6： | 1 |
| 12 | MagrìClass-modeling using Kohonen artificial neural networks显示文摘 | MARINI F ZUPAN J ANTONIO L | 2005 | Analytica Chimica Acta2005，544，12： | 1 |
| 13 | Mesenchymal stem eells overexpressing IFN-β inhibit breast eaneer growth and metastases through stoat3 signaling in a syngeneie tumor model显示文摘 | Ling X Marini F Konoplewt M | 2010 | Caneer Microenviron2010，3，1： | 1 |
| 14 | Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects显示文摘 | Simorini F Marini AM Taliani S | 2012 | CurrTop Med Chern2012，12，4： | 1 |
| 15 | Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C显示文摘 | Ridolfi F Abbattista T Marini F | | 0，，10： | 1 |
| 16 | Second-line treatment options in non-small cell lung cancer:a comparison of cytotoxic agents and targeted therapies显示文摘 | de Marinis F De Santis S De Petris L | | 0，，1： | 1 |
| 17 | Phase III randomized trial comparing three platinum-based doublets in advanced nonsmall-cell lung cancer显示文摘 | Scagliotti G V De Marinis F Rinaldi M | 2002 | J Clin Oncol2002，20，21： | 1 |
| 18 | PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treamaent with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer显示文摘 | Paz-Ares LG De Marinis F Dediu MJ | 2013 | J ClinOncol2013，31，23： | 1 |
| 19 | Clinical evidence for second and third-line treatment options in advanced non small cell lung cancer显示文摘 | de Marinis F Grossi F | 2008 | Oncologist2008，13，1： | 1 |
| 20 | Two families of mixed finite elements for second order elliptic problems显示文摘 | F Breezi J Douglas Jr L D Marini | 1985 | Numer Math1985，47，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员